Taj Hafiza Munazza, Talib Maryam, Siddiqa Sania, Sarfraz Azza, Sarfraz Zouina, Robles-Velasco Karla, Cherrez-Ojeda Ivan
Research and Publications, Fatima Jinnah Medical University, Lahore 54000, Pakistan.
Research, Services Institute of Medical Sciences, Lahore 54000, Pakistan.
Healthcare (Basel). 2022 Nov 2;10(11):2199. doi: 10.3390/healthcare10112199.
Ofatumumab is a monoclonal antibody that reduces the level of B cells that alter the progression of relapsing multiple sclerosis. Originally approved by the Food and Drug Administration (FDA) in August 2020, this meta-analysis determines the outcomes of four randomized controlled trials (RCTs) for endline outcomes of Gadolinium-enhancing T1 lesions on MRI scans reported as Cohen’s d and relapse rate reported as risk ratio. All four RCTs reported favorable findings of gadolinium-enhancing T1 lesions (Cohen’s d = −0.44, p < 0.00001). The relapse rate was reduced by 46% post ofatumumab administration (RR = 0.54, p < 0.00001). With 14 ongoing trials in this area, more data is required to consolidate our findings.
奥法妥木单抗是一种单克隆抗体，可降低改变复发型多发性硬化症病程的B细胞水平。该药物最初于2020年8月获得美国食品药品监督管理局（FDA）批准，本荟萃分析确定了四项随机对照试验（RCT）的结果，这些试验的终末结局为MRI扫描上钆增强T1病变，以科恩d值报告，复发率以风险比报告。所有四项RCT均报告了钆增强T1病变的有利结果（科恩d值 = -0.44，p < 0.00001）。奥法妥木单抗给药后复发率降低了46%（风险比 = 0.54，p < 0.00001）。该领域有14项正在进行的试验，需要更多数据来巩固我们的研究结果。
